Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

BACKGROUND: Novel therapies are needed to improve the poor prognosis of patients with recurrent and/or metastatic squamous cell cancer of the head and neck (SCCHN). METHODS: ADVANTAGE is a phase I/II, multicentre study evaluating the integrin inhibitor cilengitide combined with cetuximab and platinu...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermorken, J B, Guigay, J, Mesia, R, Trigo, J M, Keilholz, U, Kerber, A, Bethe, U, Picard, M, Brummendorf, T H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111165/
https://www.ncbi.nlm.nih.gov/pubmed/21540865
http://dx.doi.org/10.1038/bjc.2011.152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111165/
https://www.ncbi.nlm.nih.gov/pubmed/21540865
http://dx.doi.org/10.1038/bjc.2011.152

Ejemplares similares